Lipid Lowering Effects of Niacin and Lovastatin Given Alone or With Cholestyramine in Renal Transplant Patients.{private}

Lal, Sunder M.; Habib, Shaimaa A

doi:10.1097/00002480-199903000-00226

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in another small study a combination of a high dose of rosuvastatin with cholestyramine did not provide significantly better LDL‐lowering than rosuvastatin alone [12]. Triple combination of lovastatin, nicotinic acid and cholestyramine also failed in a small study to lower LDL‐cholesterol to the recommended goal levels [13]. Comparison of combination therapy vs. placebo is for sure not appropriate, but it has been shown that cholestyramine together with gemfibrozil and niacin significantly reduces cardiovascular events when compared with placebo [14].…”

Section: Methodsmentioning

confidence: 99%

Combined therapy in the treatment of dyslipidemia

Reiner

2010

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

This systematic review analyses the efficacy, tolerability and safety of combinations of different medicines used to treat dyslipidemias in clinical practice. A PubMed search up to January 2009, was conducted to identify relevant studies. Criteria used to identify studies included (1) English language, (2) published studies with original data or meta-analyses in peer-reviewed journals. Although statin treatment is a mainstay of dyslipidemia management today, complementary effects of other lipid-lowering and/or HDL-cholesterol-raising therapies might substantially increase the clinical benefits not only in the small minority of patients with severe dyslipidemias but in others as well. These therapies include combinations with bile acid sequestrants (cholestyramine, colestipol, colesevelam), ezetimibe, niacin, plant sterols, fibrates (fenofibrate, bezafibrate, gemfibrozil), and prescription omega-3 fatty acids. Therapeutic approaches which incorporate the use of multiple drugs combinations for dyslipidemia treatment should be more widely adopted since combination therapy might offer a means to increase the number of patients able to meet their lipoprotein goals according to the guidelines. However, it has to be stated that for most of these combination therapies data on cardiovascular outcomes are still lacking.

show abstract

Section: Methodsmentioning

confidence: 99%

Combined therapy in the treatment of dyslipidemia

Reiner

2010

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Lovastatin at a daily dose of 20-30 mg decreased TC and LDL-C levels by 27%, TG levels by 28% and apo B levels by 35%, while increasing HDL-C concentration by 17% and apo A-I levels by 24% [114]. However, a small study evaluating the co-administration of lovastatin with nicotinic acid and cholestyramine showed that combined treatment failed to achieve the goals recommended by the National Cholesterol Education Program (Adult Treatment Panel III) (NCEP ATP III) guidelines [125].…”

Section: B Lovastatinmentioning

confidence: 99%

Statins and Solid Organ Transplantation

Gazi¹,

Liberopoulos²,

Athyros³

et al. 2006

CPD

View full text Add to dashboard Cite

Dyslipidaemia is common in solid organ transplant recipients and its presence is associated with chronic rejection and accelerated atherosclerosis, leading to an increased prevalence of cardiovascular disease (CVD). CVD is a major cause of morbidity and mortality in transplant recipients. It is therefore of interest and clinical value to introduce agents that effectively and safely reduce the incidence of this outcome. In the present review we consider the potential benefits of statin administration in adults who have undergone solid organ (mainly renal, heart and liver) transplantation, as well as in paediatric transplant patients. We also briefly review the effects of combination therapy with ezetimibe and statins in this population. Overall, statins are efficient and safe drugs for the management of dyslipidaemias in transplant populations, and in most trials they had a beneficial effect on long-term survival rates, CVD events and rejection rates. The transplanted population is different from other patient groups, mostly due to concomitant immunosuppressive therapy. Statins, at an appropriate dosage, should be prescribed to dyslipidaemic transplanted patients but they should be closely monitored for adverse effects.

show abstract

Lipid Lowering Effects of Niacin and Lovastatin Given Alone or With Cholestyramine in Renal Transplant Patients.{private}

Cited by 2 publications

References 0 publications

Combined therapy in the treatment of dyslipidemia

Combined therapy in the treatment of dyslipidemia

Statins and Solid Organ Transplantation

Contact Info

Product

Resources

About